Chiral Ionic Liquid Catalyzed α-Alkylation
Compound 33: Yield 27 mg, 67%; Ͼ99:1 dr; white solid. [α]2D0 = –78
(75% ee; c = 0.5, CHCl3). H NMR (300 MHz, CDCl3): δ = 0.89 (c = 0.5, CHCl3). H NMR (300 MHz, CDCl3): δ = 1.62–1.94 (m,
Compound 37: Yield 36 mg, 57%; 90:10 dr; white solid. [α]2D0 = –33
1
1
(t, J = 6.65 Hz, 3 H, CH3), 1.27–1.40 (m, 6 H, 3ϫCH2), 1.60–1.70
4 H, 2ϫCH2), 2.22–2.25 (m, 1 H, CH), 2.51–2.66 (m, 2 H, CH2),
(m, 3 H, CH2 + CH), 1.76–1.84 (m, 2 H, CH2), 2.23 (d, J = 2.86 [s, 6 H, N(CH3)2], 2.89 [s, 6 H, N(CH3)2], 3.19–3.22 (m, 1 H,
7.95 Hz, 2 H, CH2), 2.86 [s, 6 H, N(CH3)2], 2.89 [s, 6 H, CH), 3.49 (d, J = 4.90 Hz, 1 H, CH), 4.09 (d, J = 12.04 Hz, 1 H,
N(CH3)2], 3.17–3.22 (m, 1 H, CH), 4.15 (d, J = 11.92 Hz, 1 H,
Ph2CH), 6.60–6.67 (m, 4 H, 4ϫArH), 7.11–7.17 (m, 4 H,
Ph2CH), 5.17 (s, 4 H, 2ϫPhCH2), 6.59–6.69 (m, 4 H, 4ϫArH),
7.07–7.12 (m, 4 H, 4ϫArH), 7.30–7.34 (m, 10 H, 10ϫArH) ppm.
4ϫArH) ppm. 13C NMR (75 MHz, CDCl3): δ = 14.1, 22.7, 27.2, 13C NMR (75 MHz, CDCl3): δ = 24.1, 28.3, 39.6, 40.6, 40.7, 42.9,
29.0, 29.2, 36.3, 40.6, 40.7, 40.8, 46.2, 49.7, 55.2, 112.8, 112.9,
128.5, 130.9, 131.4, 149.1, 149.2, 214.2 ppm. IR (KBr): ν = 2923,
49.6, 54.7, 56.6, 67.3, 112.8, 113.0, 128.3, 128.3, 128.4, 128.5, 128.5,
128.7, 130.4, 135.2, 149.1, 149.2, 167.6, 167.7, 211.8 ppm. IR
˜
2859, 2805, 1700, 1614, 1522, 1447, 1351, 805 cm–1. HRMS (EI): (KBr): ν = 2926, 2857, 2801, 1734, 1709, 1613, 1519, 1455, 1348,
˜
calcd. for C27H38N2O [M] 406.2984; found 406.2988. The enantio-
mer excess was determined by HPLC analysis with a Chiralpak
AD-H column; λ = 254 nm; eluent: iPrOH/n-hexane (1:9, v/v); flow
rate = 0.5 mL/min; tR = 15.40 min (minor), 17.89 min (major).
807 cm–1. HRMS (EI): calcd. for C40H44N2O5 [M] 632.3250; found
632.3256. We failed to determine the ee.
Compound 38: Yield 22.5 mg, 50%; Ͼ99:1 dr; white solid. [α]2D0
=
–47.6 (59% ee; c = 0.5, CHCl3). 1H NMR (300 MHz, CDCl3): δ =
1.62–1.67 (m, 2 H, CH2), 1.69–1.75 (m, 2 H, CH2), 2.15–2.30 (m,
2 H, CH2), 2.19 (s, 6 H, 2ϫCH3), 2.74–2.82 (m, 1 H, CH), 2.87 [s,
6 H, N(CH3)2], 2.90 [s, 6 H, N(CH3)2], 3.23–3.30 (m, 1 H, CH),
3.75 (d, J = 10.35 Hz, 1 H, CH), 4.11 (d, J = 11.83 Hz, 1 H,
Ph2CH), 6.61–6.67 (m, 4 H, 4ϫArH), 7.10–7.16 (m, 4 H,
4ϫArH) ppm. 13C NMR (75 MHz, CDCl3): δ = 25.1, 28.8, 29.6,
30.1, 40.0, 40.6, 40.7, 43.5, 49.5, 54.8, 73.9, 112.8, 112.9, 128.3,
128.4, 130.7, 130.8, 149.1, 149.2, 203.0, 203.1, 211.5 ppm. IR
Compound 34: Yield 33 mg, 77%; Ͼ99:1 dr; white solid. [α]2D0 = –42
1
(79% ee; c = 0.1, CHCl3). H NMR (300 MHz, CDCl3): δ = 1.77–
1.88 (m, 2 H, CH2), 1.93–1.98 [m, 1 H, C(H)H], 2.11–2.26
[m, 1 H, C(H)H], 2.40 [dd, J = 12.77, 3.78 Hz, 1 H, C(H)H], 2.79
[t, J = 12.80 Hz, 1 H, C(H)H], 2.88 [s, 6 H, N(CH3)2], 2.91 [s, 6 H,
N(CH3)2], 3.01–3.13 (m, 1 H, CH), 3.30–3.34 (m, 1 H, PhCH), 4.30
(d, J = 12.07 Hz, 1 H, Ph2CH), 6.64–6.71 (m, 4 H, 4ϫArH), 7.18–
7.24 (m, 4 H, 4ϫArH), 7.26–7.30 (m, 3 H, 3ϫArH), 7.35–7.40
(m, 2 H, 2ϫArH) ppm. 13C NMR (75 MHz, CDCl3): δ = 28.2,
29.1, 40.6, 40.7, 46.1, 46.3, 50.0, 54.9, 112.9, 113.0, 126.6, 126.7,
(KBr): ν = 2933, 2856, 2793, 1695, 1614, 1520, 1482, 1443, 1353,
˜
808 cm–1. HRMS (EI): calcd. for C28H36N2O3 [M] 448.2726; found
448.2730. The enantiomer excess was determined by HPLC analy-
sis with a Chiralpak AD-H column; λ = 254 nm; eluent: iPrOH/n-
hexane (1:9, v/v); flow rate = 1.0 mL/min; tR = 25.83 min (minor),
28.10 min (major).
128.4, 128.5, 128.7, 144.5, 149.2, 213.4 ppm. IR (KBr): ν = 2924,
˜
2859, 2802, 1700, 1613, 1520, 1446, 1351, 805 cm–1. HRMS (EI):
calcd. for C29H34N2O [M] 426.2671; found 426.2676. The enantio-
mer excess was determined by HPLC analysis with a Chiralpak
OD-H column; λ = 254 nm; eluent: iPrOH/n-hexane (1:9, v/v); flow
rate = 0.5 mL/min; tR = 22.98 min (major), 30.62 min (minor).
Compound 39: Yield 33 mg, 75%; Ͼ99:1 dr; white solid. [α]2D0 = –90
1
(84% ee; c = 0.2, CHCl3). H NMR (300 MHz, CDCl3): δ = 1.48–
1.53 [m, 1 H, C(H)H], 1.58 (s, 3 H, CH3), 1.60 (s, 3 H, CH3), 1.62–
1.80 (m, 2 H, CH2), 1.87–1.92 [m, 1 H, C(H)H], 2.11–2.18 (m, 1
H, CH), 2.31–2.41 (m, 2 H, CH2), 2.86 [s, 6 H, N(CH3)2], 2.88 [s,
6 H, N(CH3)2], 3.20–3.25 (m, 1 H, CH), 4.03 (d, J = 12.07 Hz,
1 H, Ph2CH), 6.60–6.66 (m, 4 H, 4ϫArH), 7.10–7.14 (m, 4 H,
4ϫArH) ppm. 13C NMR (75 MHz, CDCl3): δ = 20.9, 22.7, 24.1,
27.8, 40.1, 40.6, 40.7, 48.0, 49.9, 54.3, 90.6, 112.8, 113.0, 128.3,
Compound 35: Yield 31 mg, 67%; Ͼ99:1 dr; white solid. [α]2D0 = –37
(76% ee; c = 0.1, CHCl3). H NMR (300 MHz, CDCl3): δ = 1.74–
1
1.94 [m, 3 H, CH2 + C(H)H], 2.05–2.18 [m, 1 H, C(H)H], 2.34
[dd, J = 12.71, 3.67 Hz, 1 H, C(H)H], 2.71 [t, J = 12.71 Hz, 1 H,
C(H)H], 2.86 [s, 6 H, N(CH3)2], 2.88 [s, 6 H, N(CH3)2], 2.97–3.08
(m, 1 H, CH), 3.27–3.31 (m, 1 H, PhCH), 4.24 (d, J = 12.01 Hz, 1
H, Ph2CH), 6.60–6.67 (m, 4 H, 4ϫArH), 7.14–7.20 (m, 6 H,
6ϫArH), 7.25–7.32 (m, 2 H, 2ϫArH) ppm. 13C NMR (75 MHz,
CDCl3): δ = 28.4, 29.0, 40.7, 40.8, 45.6, 46.3, 50.1, 54.9, 112.9,
113.1, 128.1, 128.5, 128.6, 128.9, 130.3, 131.0, 132.44, 143.0, 149.4,
128.4, 129.6, 130.4, 149.3, 149.3, 211.7 ppm. IR (KBr): ν = 2985,
˜
2942, 2884, 2799, 1705, 1613, 1533, 1522, 1479, 1446, 1399, 1348,
807 cm–1. HRMS (ESI): clacd. for C26H36N3O3 [M + H+] 438.2757;
found 438.2762. The enantiomer excess was determined by HPLC
analysis on a Chiralpak AS-H column; λ = 254 nm; eluent: iPrOH/
n-hexane (1:4, v/v); flow rate = 1.0 mL/min; tR = 11.06 min (major),
12.66 min (minor).
Compound 40: Yield 32.5 mg, 99%; white solid. [α]2D0 = –9.6 (34%
ee; c = 0.5, CHCl3). 1H NMR (300 MHz, CDCl3): δ = 2.11 (s, 3
H, CH3), 2.89 [s, 6 H, N(CH3)2], 2.90 [s, 6 H, N(CH3)2], 3.3 (br., 1
H, OH), 4.27 (d, J = 4.38 Hz, 1 H, Ph2CH), 4.79 (d, J = 4.29 Hz,
1 H, CH), 6.63 (d, J = 8.70 Hz, 2 H, 2ϫArH), 6.68 (d, J = 8.70 Hz,
2 H, 2ϫArH), 7.12 (d, J = 8.67 Hz, 2ϫArH), 7.23 (d, J = 8.67 Hz,
2ϫArH) ppm. 13C NMR (75 MHz, CDCl3): δ = 26.5, 40.6, 40.7,
52.1, 80.3, 112.6, 112.8, 127.5, 129.0, 129.7, 130.0, 149.3, 149.5,
149.4, 213.0 ppm. IR (KBr): ν = 2925, 2856, 2798, 1700, 1614,
˜
1520, 1486, 1447, 1348, 808 cm–1. The enantiomer excess was deter-
mined by HPLC analysis with a Chiralpak AD-H column; λ =
254 nm; eluent: iPrOH/n-hexane (1:4, v/v); flow rate = 0.5 mL/min;
tR = 20.15 min (major), 21.87 min (minor).
Compound 36: Yield 34 mg, 66%; 91:9 dr; white solid. [α]2D0 = –51
1
(69% ee; c = 0.5, CHCl3). H NMR (300 MHz, CDCl3): δ = 1.26
(td, J = 7.19, 0.90 Hz, 6 H, 2ϫCH3), 1.64–1.90 (m, 4 H, 2ϫCH2),
2.16–2.26 (m, 1 H, CH), 2.50–2.62 (m, 2 H, CH2), 2.82 [s, 6 H,
N(CH3)2], 2.85 [s, 6 H, N(CH3)2], 3.20–3.24 (m, 1 H, CH), 3.36 (d,
J = 6.90 Hz, 1 H, CH), 4.13–4.23 (m, 5 H, 2ϫOCH2 + Ph2CH),
6.57–6.69 (m, 4 H, 4ϫArH), 7.10–7.16 (m, 4 H, 4ϫArH) ppm.
13C NMR (75 MHz, CDCl3): δ = 14.1, 24.1, 28.3, 39.5, 40.5, 40.6,
42.8, 49.6, 54.6, 56.6, 61.5, 112.7, 112.9, 128.3, 128.4, 130.3, 130.8,
209.4 ppm. IR (KBr): ν = 3462, 3381, 2951, 2914.88, 2883, 2795,
˜
1716, 1696, 1613, 1520, 1482, 1443, 1351, 794 cm–1. HRMS (ESI):
calcd. for C20H27N2O2 [M + H+] 327.2073; found 327.2077. The
enantiomer excess was determined by HPLC analysis with a Chi-
ralpak AD-H column; λ = 254 nm; eluent: iPrOH/n-hexane (1:9,
v/v); flow rate = 1.0 mL/min; tR = 26.08 min (major), 28.90 min
(minor).
149.1, 149.2, 167.8, 167.9, 211.9 ppm. IR (KBr): ν = 2980, 2935,
˜
2857, 2797, 1750, 1729, 1706, 1613, 1564, 1519, 1479, 1445, 1347,
808 cm–1. HRMS (EI): calcd. for C30H40N2O5 [M] 508.2937; found
508.2942. The enantiomer excess was determined by HPLC analy-
sis with a Chiralpak AS-H column; λ = 254 nm; eluent: iPrOH/n-
hexane (1:4, v/v); flow rate = 1.0 mL/min; tR = 17.50 min (minor),
30.07 min (major).
Supporting Information (see also the footnote on the first page of
this article): 1H and 13C NMR spectra and HPLC analyses of prod-
ucts 30–41.
Eur. J. Org. Chem. 2010, 4876–4885
© 2010 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
www.eurjoc.org
4883